BCI
EBS icon

Brinker Capital Investments’s Emergent Biosolutions EBS Stock Holding History

Brinker Capital Investments’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,499
Closed -$224K – 1193
2020
Q4 		$224K Buy
+2,499
New +$229K ﹤0.01% 971

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brinker Capital Investments's EBS Position: Q1 2021 in Review

Brinker Capital Investments sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 2,499 shares — an estimated $224K sold.

Brinker Capital Investments first reported a position in EBS in Q4 2020 and held it in 1 quarter. The position peaked at $224K in Q4 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

  • Brinker Capital Investments reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
  • Brinker Capital Investments sold 2,499 Emergent Biosolutions shares in Q1 2021, an estimated $224K.
  • Brinker Capital Investments first reported a position in Emergent Biosolutions in Q4 2020 and held it in 1 quarter.
  • Brinker Capital Investments's Emergent Biosolutions position peaked at $224K in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on Brinker Capital Investments's 13F filing for Q1 2021, filed 12 May 2021.